Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Bristol-Myers, Pfizer Says Eliquis Late-Stage Trial Meets Main Goal

RELATED NEWS
Trade BMY now with 

Bristol-Myers Squibb Co. (BMY: Quote) and Pfizer Inc. (PFE: Quote) Sunday said its anti-clotting drug Eliquis proved to be as effective as standard therapy and caused significantly less bleeding complications in in treating patients with acute venous thromboembolism.

Eliquis met the main endpoint of the trial by demonstrating that it is not inferior to the current standard of care, ainitial parenteral enoxaparin treatment overlapped with warfarin therapy, in the reduction of recurrence of acute venous thromboembolism, or VTE, and related deaths.

Eliquis also met the primary safety endpoint of superiority for major bleeding, with a 69 percent relative risk reduction compared to current standard of care.

Eliquis, or apixaban, is an anticoagulant that was jointly developed by Bristol-Myers Squibb and Pfizer. Eliquis is approved for prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery in the EU and other countries, but the drug has not been is not approved for this indication in the U.S.

"The study results showed that apixaban, as a single-agent, has comparable efficacy with significantly fewer major bleeding events with respect to the standard of care," said Dr. Giancarlo Agnelli, the lead investigator of the study. "Together these studies represent exciting data in the field of VTE treatment and indicate that apixaban may offer an important potential alternative in both acute and extended anticoagulation therapy for VTE patients."

Venous thromboembolism encompasses two serious conditions: deep vein thrombosis (DVT), a blood clot in a vein, usually in the leg; and pulmonary embolism (PE), a blood clot blocking one or more vessels in the lungs. Around 900,000 patients in the U.S. and about 1 million patients in the EU are diagnosed every year with VTE.

The study, dubbed AMPLIFY, (Apixaban for the initial Management of PuLmonary embolIsm and deep vein thrombosis as First-line therapY), included 5,395 patients. The study tested 10 mg of Eliquis twice daily for seven days followed by 5 mg twice daily thereafter compared to current standard of care.

PFE closed Friday at $28.01, down $0.17 or 0.60%, while BMY closed at $44.69, down $1.61 or 3.48%, both on the NYSE.

Register
To receive FREE breaking news email alerts for Bristol-Myers Squibb Co. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Alaska Congressman Don Young, R-Ak., is once again making headlines with comments linking the state's high suicide rate to an increase in government assistance. Young told an audience at a senior center on Wednesday that the suicide problem didn't exist until there was "largesse" from the government. After moving sharply higher at the open, stocks have seen further upside over the course of the trading day on Thursday. The strong upward move on the day has more than offset the pullback that was seen in the previous session. Suggesting moderate growth in the short-term, the Conference Board released a report on Thursday showing that its index of leading U.S. economic indicators rose by more than economists had anticipated in the month of September.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.